1887

Abstract

The European Study Group on (ESGCD) conducted a prospective study in 2005 to monitor and characterize strains circulating in European hospitals, collecting 411 isolates. Eighty-three of these isolates, showing resistance or intermediate resistance to moxifloxacin (MX), were selected for this study to assess susceptibility to other fluoroquinolones (FQs) and to analyse the genes, encoding the DNA gyrase subunits GyrA and GyrB. Twenty MX-susceptible isolates from the surveillance study were included for comparison. Overall, one amino acid substitution in GyrA (Thr82 to Ile) and four different substitutions in GyrB (Ser416 to Ala, Asp426 to Asn, Asp426 to Val and Arg447 to Lys) were identified. A high level of resistance (MIC ≥32 μg ml) to MX, ciprofloxacin (CI), gatifloxacin (GA) and levofloxacin (LE) was found in 68 isolates showing the amino acid substitution Thr82 to Ile in GyrA, in eight isolates with the substitutions Thr82 to Ile in GyrA and Ser416 to Ala in GyrB, in two isolates showing the substitution Asp426 to Asn in GyrB and in one isolate with Asp426 to Val in GyrB. The remaining four isolates showed high MICs for CI and LE, but different MIC levels for MX and GA. In particular, intermediate levels of resistance to MX were shown by two isolates, one with the substitution Thr82 to Ile in GyrA, and one showing Asp426 to Asn in GyrB. The substitution Arg447 to Lys in GyrB was found in two strains resistant to MX, CI and LE but susceptible to GA. No substitutions in GyrA were found in the FQ-susceptible strains, whereas two strains showed the amino acid change Ser416 to Ala in GyrB. Thr82 to Ile was the most frequent amino acid change identified in the isolates examined. In contrast to previous observations, 10 % of the isolates showed this substitution in association with Ser416 to Ala in GyrB. The other amino acid changes found were characteristic of a few strains belonging to certain types and/or countries. Two new substitutions for , Ser416 to Ala and Arg447 to Lys, were found in GyrB. Whereas the former does not seem to have a key role in resistance, since it was also detected in susceptible strains, the latter substitution occurred in the same position where other amino acid variations take place in resistant and other strains. A large number of isolates now show an alarming pattern of resistance to the majority of FQs currently used in hospitals and outpatient settings, therefore judicious use of these antibiotics and continuous monitoring of resistance are necessary.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.47738-0
2008-06-01
2019-10-23
Loading full text...

Full text loading...

/deliver/fulltext/jmm/57/6/784.html?itemId=/content/journal/jmm/10.1099/jmm.0.47738-0&mimeType=html&fmt=ahah

References

  1. Ackermann, G., Tang, Y. J., Kueper, R., Heisig, P., Rodloff, A. C., Silva, J., Jr & Cohen, S. H. ( 2001; ). Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA. Antimicrob Agents Chemother 45, 2348–2353.[CrossRef]
    [Google Scholar]
  2. Ackermann, G., Tang-Feldman, Y. J., Schaumann, R., Henderson, J. P., Rodloff, A. C., Silva, J. & Cohen, S. H. ( 2003; ). Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in Clostridium difficile. Clin Microbiol Infect 9, 526–530.[CrossRef]
    [Google Scholar]
  3. Barbut, F., Mastrantonio, P., Delmee, M., Brazier, J., Kuijper, E. & Poxton, I., on behalf of the European Study Group on Clostridium difficile (ESGCD) ( 2007; ). Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 13, 1048–1057.[CrossRef]
    [Google Scholar]
  4. Biller, P., Shank, B., Lind, L., Brennan, M., Tkatch, L., Killgore, G., Thompson, A. & McDonald, L. C. ( 2007; ). Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol 28, 198–201.[CrossRef]
    [Google Scholar]
  5. CLSI ( 2007; ). Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria. Approved standard M11–A7, 7th edn. Wayne, PA: Clinical and Laboratory Standards Institute.
  6. Dridi, L., Tankovic, J., Burghoffer, B., Barbut, F. & Petit, J. C. ( 2002; ). gyrA and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother 46, 3418–3421.[CrossRef]
    [Google Scholar]
  7. Drudy, D., Quinn, T., O'Mahony, R., Kyne, L., O'Gaora, P. & Fanning, S. ( 2006; ). High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J Antimicrob Chemother 58, 1264–1267.[CrossRef]
    [Google Scholar]
  8. Drudy, D., Kyne, L., O'Mahony, R. & Fanning, S. ( 2007; ). gyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027. Emerg Infect Dis 13, 504–505.[CrossRef]
    [Google Scholar]
  9. Friedman, S. M., Lu, T. & Drlica, K. ( 2001; ). Mutation in the DNA gyrase A gene of Escherichia coli that expands the quinolone resistance-determining region. Antimicrob Agents Chemother 45, 2378–2380.[CrossRef]
    [Google Scholar]
  10. Gaynes, R., Rimland, D., Killum, E., Lowery, H. K., Johnson, T. M., II, Killgore, G. & Tenover, F. C. ( 2004; ). Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 38, 640–645.[CrossRef]
    [Google Scholar]
  11. Golledge, C. L., Carson, C. F., O'Neill, G. L., Bowman, R. A. & Riley, T. V. ( 1992; ). Ciprofloxacin and Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 30, 141–147.[CrossRef]
    [Google Scholar]
  12. Hooper, D. C. ( 1999; ). Mechanisms of fluoroquinolone resistance. Drug Resist Updat 2, 38–55.[CrossRef]
    [Google Scholar]
  13. Kuijper, E. J., Coignard, B. & Tull, P., ESCMID Study Group for Clostridium difficile; EU Member States; European Centre for Disease Prevention and Control ( 2006; ). Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 12 (Suppl. 6), 2–18.
    [Google Scholar]
  14. McCusker, M. E., Harris, A. D., Perencevich, E. & Roghmann, M. C. ( 2003; ). Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 9, 730–733.[CrossRef]
    [Google Scholar]
  15. Muto, C. A., Pokrywka, M., Shutt, K., Mendelsohn, A. B., Nouri, K., Posey, K., Roberts, T., Croyle, K., Krystofiak, S. & other authors ( 2005; ). A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 26, 273–280.[CrossRef]
    [Google Scholar]
  16. Ruiz, J. ( 2003; ). Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 51, 1109–1117.[CrossRef]
    [Google Scholar]
  17. Rupnik, M., Avesani, V., Janc, M., von Eichel-Streiber, C. & Delmee, M. ( 1998; ). A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 36, 2240–2247.
    [Google Scholar]
  18. Stubbs, S. L., Brazier, J. S., O'Neill, G. L. & Duerden, B. I. ( 1999; ). PCR targeted to the 16S–23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 37, 461–463.
    [Google Scholar]
  19. Yip, C., Loeb, M., Salama, S., Moss, L. & Olde, J. ( 2001; ). Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol 22, 572–575.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.47738-0
Loading
/content/journal/jmm/10.1099/jmm.0.47738-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error